Oramed Pharmaceuticals Inc.

Oramed Pharmaceuticals Inc.

3.90
USD
+0.19
(+5.12%)
4.17EPS
1.13P/E
198.72MMarket Cap
Mar 03Next Earn

Total Valuation

USD

As of June 30, 2026, Oramed Pharmaceuticals Inc. carries a market capitalization of 198.72M, placing it among publicly traded companies globally. Its enterprise value stands at 148.84M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap198.72M
Enterprise Value148.84M

Important Dates

Oramed Pharmaceuticals Inc.'s next confirmed earnings release is scheduled for March 3, 2027.

Earnings Date3/3/2027

Share Statistics

As of June 30, 2026, Oramed Pharmaceuticals Inc. has 41.31M shares outstanding.

Shares Outstanding41.31M

Valuation Ratios

As of June 30, 2026, Oramed Pharmaceuticals Inc. trades at a trailing price-to-earnings ratio of 1.13.

PE Ratio1.13
PB Ratio0.63
P/TBV Ratio0.63
P/FCF Ratio-28.25
P/OCF Ratio-37.89

Financial Position

As of June 30, 2026, Oramed Pharmaceuticals Inc. maintains a current ratio of 4.98, meaning it holds 5.0x the short-term assets needed to cover near-term liabilities.

Current Ratio4.98
Quick Ratio4.77
Debt / Equity0.23
Debt / EBITDA-0.05

Financial Efficiency

Over the twelve months ended June 30, 2026, Oramed Pharmaceuticals Inc. posted a return on equity (ROE) of 74.10, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) is negative at -4.81, so the business is destroying capital rather than earning a return above its cost of capital. Return on assets (ROA) stands at 65.82, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 73.99, useful for judging operating efficiency across full business cycles. The company generates approximately - - in revenue per employee across its workforce of 13.00, a quick read on workforce productivity versus industry peers.

Return on Equity (ROE)74.10
Return on Assets (ROA)65.82
Return on Invested Capital (ROIC)-4.81
Return on Capital Employed (ROCE)73.99
Employee Count13.00

Taxes

USD

Over the twelve months ended June 30, 2026, Oramed Pharmaceuticals Inc. recorded 45.41M in income tax expense. That works out to an effective tax rate of 20.62, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 220.28M, leaving 174.87M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax45.41M
Effective Tax Rate20.62

Stock Price Statistics

USD

As of the close on November 16, 2026, Oramed Pharmaceuticals Inc.'s stock has gained approximately 67.38% over the past 52 weeks. The 50-day moving average sits at 4.34, while the 200-day moving average is 4.06.

52-Week Price Change67.38%
50-Day Moving Average4.34
200-Day Moving Average4.06

Income Statement

USD

Over the twelve months ended June 30, 2026, Oramed Pharmaceuticals Inc. generated - - in revenue and converted that into 174.87M in net income, yielding earnings per share of 4.17. EBITDA reached -14.40M, while operating income came in at -14.52M.

Operating Income-14.52M
Pretax Income220.28M
Net Income174.87M
EBITDA-14.40M
EBIT-14.52M
Earnings Per Share (EPS)4.17

Balance Sheet

USD

As of June 30, 2026, Oramed Pharmaceuticals Inc. holds 50.61M in cash and equivalents against 733,000.00 in total debt, resulting in a net debt position of -15.24M. Total book value stands at 317.47M, with working capital of 42.68M providing operational flexibility.

Cash & Cash Equivalents50.61M
Total Debt733,000.00
Net Debt-15.24M
Equity (Book Value)317.47M
Book Value Per Share7.68
Working Capital42.68M

Cash Flow

USD

Oramed Pharmaceuticals Inc. produced -5.21M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.93M in capital expenditures, free cash flow totaled -7.14M - equivalent to -0.17 per share.

Operating Cash Flow-5.21M
Capital Expenditures-1.93M
Free Cash Flow-7.14M
FCF Per Share-0.17

Dividends & Yields

USD

Over the twelve months ended June 30, 2026, Oramed Pharmaceuticals Inc. paid dividends of 0.25 per share. The dividend payout ratio of 5.97 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -3.54: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 8.40, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Oramed Pharmaceuticals Inc. shareholders.

Dividend Per Share0.25
Payout Ratio5.97
Shareholder Yield8.40
FCF Yield-3.54

Stock Splits

Oramed Pharmaceuticals Inc.'s most recent stock split took place on January 23, 2013 with a 12:1 split ratio.

Last Split Date1/23/2013
Split Ratio12:1

Scores

As of June 30, 2026, Oramed Pharmaceuticals Inc. has an Altman Z-Score of 2.27, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score2.27